Pelthos Therapeutics Inc. (PTHS) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $109.70M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $2.08M; Retained Earnings (Accumulated Deficit)USD $-113.28M.
- 2026-03-31: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $106.94M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $2.19M; Retained Earnings (Accumulated Deficit)USD $-89.87M.
- 2025-12-31: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $103.67M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $0.00; Retained Earnings (Accumulated Deficit)USD $-64.79M.
- 2025-09-30: Common Stock, Value, IssuedUSD (m); Additional Paid in CapitalUSD $101.38M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD $-43.13M.
Pelthos Therapeutics Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $109.70M | $2.08M | $-113.28M | $-1.50M | 3 month · $2.76M | (m) |
| 2026-03-31 | $0.00 | $106.94M | $2.19M | $-89.87M | $19.27M | 3 month · $1.24M | 3 month · $1.36M |
| 2025-12-31 | $0.00 | $103.67M | $0.00 | $-64.79M | $38.88M | 12 month · $3.95M | (m) |
| 2025-09-30 | (m) | $101.38M | (m) | $-43.13M | $58.25M | 3 month · $2.00M | (m) |
| 2025-06-30 | $67.00 | $20.40M | (m) | $-26.89M | $-6.50M | 3 month · $394.00K | (m) |
| 2025-03-31 | $621.00 | $19.25M | (m) | $-23.44M | $-4.20M | 3 month · $404.00K | (m) |
| 2024-12-31 | $0.00 | $18.76M | (m) | $-21.48M | $-2.71M | 12 month · $1.46M | (m) |
| 2024-09-30 | $583.00 | $18.12M | (m) | $-19.55M | $-1.43M | 3 month · $395.00K | (m) |
| 2024-06-30 | $584.00 | $17.67M | (m) | $-17.85M | $-184.00K | 3 month · $366.00K | (m) |
| 2024-03-31 | $578.00 | $17.21M | (m) | $-16.08M | $1.13M | 3 month · $293.00K | (m) |
| 2023-12-31 | $391.00 | $7.07M | (m) | $-13.52M | $-6.45M | 12 month · $1.73M | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | $-5.90M | 3 month · $342.43K | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | $-4.90M | 3 month · $327.34K | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | $-4.44M | 3 month · $272.22K | (m) |
| 2022-12-31 | $111.00 | $2.43M | (m) | $-6.14M | $-3.71M | 12 month · $110.15K | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | $-3.68M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |